Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Hybrigenics' Inecalcitol Shows High Level of Tolerance
Hybrigenics successfully performs first clinical trial

Paris, April 12, 2007 - Hybrigenics announces today the first results from its Phase I clinical trial of inecalcitol, a synthetic analogue of vitamin D under development by Hybrigenics as a potential treatment for prostate cancer.

Inecalcitol was administered orally in a double-blind randomized study against placebo on 36 healthy volunteers up to 80 micrograms. No side effects were observed. In particular, there was neither hypercalcemia, nor rise in calcium levels in the urine, the usual specific dose-limiting toxicity among natural or synthetic derivatives of vitamin D. Additional higher dose levels of inecalcitol are being prepared for further testing.

This observation is in line with the lower toxicity of inecalcitol demonstrated in pre-clinical studies as compared to calcitriol, the naturally active metabolite of vitamin D3. Calcitriol is currently in Phase III clinical trial for hormone-refractory prostate cancer in combination with Taxotere(R), the first-line gold standard chemotherapeutic intravenous treatment for this indication. Calcitriol is administered orally in 45 microgram doses once a week.

'The results of our first Phase I trial position Hybrigenics as a clinical stage drug development company,' said Rémi Delansorne, CEO of Hybrigenics, 'We expect inecalcitol to be given in higher dosages than calcitriol for more efficacy combined with a better tolerance in the same prostate cancer indication.' Hybrigenics is planning to start the Phase IIa trial to determine the maximum tolerated dose of inecalcitol in hormone-refractory prostate cancer before the end of this year.

About Hybrigenics:
Hybrigenics is a biopharmaceutical company advancing its R&D programs in oncology, and providing cutting-edge discovery services to identify, validate or inhibit protein-protein interactions for customers from all life sciences.

Hybrigenics is developing inecalcitol, a synthetic vitamin D analogue more potent and less toxic than naturally active vitamin D compounds. The primary indication of interest for Hybrigenics is prostate cancer by the oral route. Hybrigenics' research focuses on internally validated Ubiquitin-Specific Proteases (USP) as an original class of oncology targets, and on drug discovery to find USP inhibitors as novel anti-cancer therapeutics.

Hybrigenics' services offer reliable Yeast Two-Hybrid screens performed on a robust ISO 9001 certified industrial platform and backed by strong bioinformatics to compile and rank the protein-protein interactions detected. Hybrigenics is also providing study design assistance or experimental work to validate the relevant interactions and to screen for small molecule inhibitors able to disrupt them.

Publisher Contact Information:

+44 1273 675100

Company profile of Hybrigenics
Past press releases of Hybrigenics.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.